|
|
|
| Efficacy of the focused ultrasound ablation combined with dinorgestrel for treating patients with adenomyosis and its influence on the immune function |
| Yichang Women and Children's Health Care Hospital, Yichang, Hubei Province, 443000 |
|
|
|
|
Abstract To investigate the effects of the focused ultrasound ablation (FUAS) combined with dinorgestrel for treating patients with adenomyosis on their pain score, anemia degree, serum markers and hormone markers levels, immune function and safety. Methods: 86 patients with adenomyosis treated in hospital were randomly divided into control group (n=43) and observation group (n=43) according to 1:1 ratio from November 2022 to November 2023. The patients in the control group were treated with FUAS alone for 3 months, and the patients in the observation group were treated with FUAS combined with dinorgestrel for 3 months. The pain score, the degree of anemia, the levels of serum indexes and hormone indexes, the immune function and the adverse reactions rate of the patients before and after treatment were compared between the two groups. Results: After treatment, the visual analogue scale score (1.47±1.03 points) of the patients in the observation group was significantly lower than that (3.66±1.46 points) of the patients in the control group. The levels of hemoglobin (117.66±10.39 g/L), immunoglobulin (Ig) G (10.36±1.29 g/L) and IgM (1.36±0.29 g/L) of the patients in the observation group were significantly higher than those (±9.22 g/L, 8.73±1.58 g/L and 0.89±0.21 g/L) of the patients in the control group. The levels of mouse double microgene-2 (1.44±0.39 kU/L), carbohydrate antigen 125 (34.97±4.11 IU/ml), vascular endothelial growth factor (82.16±15.34 pg/ml), follicle stimulating hormone (3.47±1.03 U/L), estradiol (114.28±20.11 pmol/L) and luteinizing hormone (4.27±1.05 mg/ml) of the patients in the observation group were significantly lower than those (2.36±0.47 kU/L, 44.85±4.32 IU/ml, 98.46±17.28 pg/ml, 5.26±1.14 U/L, 134.69±21.20 pmol/L and 5.64±1.12 mg/ml) of the patients in the control group. The incidence of adverse reactions (9.3%) of the patients in the observation group was significantly lower than that (27.9%) of the patients in the control group (all P<0.05). Conclusion: FUAS combined with dinorgestrel for treating the patients with adenomyosis can effectively reduce their pain degree and anemia status, improve their serum indexes, hormone indexes and immune function, and with the higher safety.
|
|
|
|
|
|
|
|
|
